In vitro cytotoxic activity of a monolacunary Wells-Dawson nanocluster against cervical carcinoma HeLa cells

2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023 (415-418)

АУТОР(И) / AUTHOR(S): Mirjana B. Čolović, Jelena J. Žakula, Lela B. Korićanac, Nada Savić, Tatjana Parac-Vogt, Danijela Z. Krstić

Е-АДРЕСА / E-MAIL: colovicm@vin.bg.ac.rs

Download Full Pdf  

DOI: 10.46793/ICCBI23.415C

САЖЕТАК / ABSTRACT:

The aim of this study was to assess in vitro cytotoxic activity of a monolacunary Wells-Dawson nanocluster, α2-K10P2W17O61.20H2O (lacunary WD) against cervical carcinoma HeLa cells as a commonly used model system for the evaluation of antitumor properties. After HeLa cells had been exposed to the investigated polyoxotungstate (the concentration range of 0.001 – 1 mM) for 24, 48, and 72 h, relative cell viability (expressed as a percentage of control) was determined. The obtained results showed that lacunary WD affected HeLa cell viability in a concentration-and time-dependent manner. IC50 values (in μM), calculated using sigmoidal fitting experimental plots, were as follows: 24.11 ± 9.95, 12.74 ± 0.096, and 11.48 ± 0.12 for 24, 48, and 72 hours treatment, respectively. In comparison with cisplatin, (positive control), IC50 values (μM) for 24 hours treatment were similar – 24.11 (lacunary WD) vs. 24.49 (cisplatin). However, after 48 and 72 hours IC50 obtained for cisplatin were found to be lower – 8.81 and 4.93 μM, respectively.
Accordingly, the studied WD polyoxotungstate could not be regarded as a superior anticancer agent in comparison with the standard chemotherapeutic. Nevertheless, this studied nanocluster deserves attention as a promising antitumor therapeutic and as a good platform for the design of next-generation metal-based anticancer agents.

КЉУЧНЕ РЕЧИ / KEYWORDS:

antitumor metallodrug, HeLa cells, in vitro cytotoxicity, monolacunary Wells-Dawson, polyoxotungstate

ЛИТЕРАТУРА / REFERENCES:

  • M.B. Čolović, M. Lacković, J. Lalatović, A.S. Mougharbel, U. Kortz, D.Z. Krstić, Polyoxometalates in biomedicine: update and overview, Current Medicinal Chemistry, 27 (2020) 362-379.

  • A. Bijelic, M. Aureliano, A. Rompel, Polyoxometalates as potential next-generation metallodrugs in the combat against cancer, Angewandte Chemie International Edition, 58 (2019) 2980−2999.

  • A.P. Ginsberg, Inorganic Syntheses, Wiley, 1990.

  • P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, Journal of the National Cancer Institute, 82 (1990) 1107-1112.